Hypertrophic obstructive cardiomyopathy-alcohol septal ablation vs. myectomy: a meta-analysis.

AIMS Our purpose is to conduct a meta-analysis of all published studies comparing alcohol septal ablation (ASA) and myectomy (MM) for drug refractory hypertrophic obstructive cardiomyopathy (HOCM). Alcohol septal ablation is a less invasive alternative to MM for relief of symptoms in patients with drug refractory HOCM. METHODS AND RESULTS An extensive search of PubMed identified five non-randomized studies comparing ASA and MM. Of 351 patients studied, 183 underwent ASA and 168 underwent MM. Patients undergoing ASA were older (mean age 54.4 +/- 6.3 vs. 45.0 +/- 4.4 years, P = 0.02). All patients were in New York Heart Association (NYHA) class II-IV. Baseline left ventricular outflow tract (LVOT) gradient was comparable (81.4 +/- 14.3 mmHg in ASA vs. 77.4 +/- 15.5 mmHg in MM, P = 0.2). Although resting LVOT gradient after septal reduction therapy in both groups was <20 mmHg at follow-up, patients undergoing MM had lower LVOT gradient (18.2 +/- 6.7 vs. 10.8 +/- 6.3 mmHg, P < 0.001). Patients in both groups had comparable improvement in NYHA class (1.5 +/- 0.3 in ASA vs. 1.3 +/- 0.2, P = 0.2) at follow-up. A higher percentage of patients undergoing ASA required permanent pacemaker (PPM) implantation for complete heart block (18.4 +/- 7.9 vs. 3.3 +/- 3.9%, P = 0.04). There was no significant in-hospital mortality difference between the two groups. CONCLUSION Alcohol septal ablation and MM provide significant reduction in LVOT gradient and NYHA functional class on mid-term follow-up. A higher percentage of patients required PPM after ASA. Randomized trials are needed to confirm current findings.

[1]  C. Stellbrink,et al.  Survival after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy (TASH): a 10 year experience , 2008, Clinical Research in Cardiology.

[2]  H. Schaff,et al.  Surgical Management of Hypertrophic Cardiomyopathy in 2007: What is New? , 2008, World Journal of Surgery.

[3]  J. Veselka.  Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: focus on safety. , 2007, Swiss medical weekly.

[4]  O. Alfieri,et al.  Alcohol septal ablation versus surgical myectomy: a patient with obstructive HCM , 2007, Nature Clinical Practice Cardiovascular Medicine.

[5]  L. Faber,et al.  Long-term follow-up after percutaneous septal ablation in hypertrophic obstructive cardiomyopathy , 2007, Clinical Research in Cardiology.

[6]  D. Fassbender,et al.  One-year follow-up of percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy in 312 patients: predictors of hemodynamic and clinical response , 2007, Clinical Research in Cardiology.

[7]  M. Haghjoo.  Long-term electrocardiographic findings in patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation. , 2007, Journal of electrocardiology.

[8]  W. O’Neill,et al.  Predictors of complete heart block after alcohol septal ablation for hypertrophic cardiomyopathy and the timing of pacemaker implantation. , 2007, Journal of interventional cardiology.

[9]  A. Tajik,et al.  Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy. , 2007, Journal of the American College of Cardiology.

[10]  J. Kuijer,et al.  Septal ablation in hypertrophic obstructive cardiomyopathy improves systolic myocardial function in the lateral (free) wall: a follow-up study using CMR tissue tagging and 3D strain analysis. , 2006, European heart journal.

[11]  J. Veselka,et al.  Impact of ethanol dosing on the long-term outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy: a single-center prospective, and randomized study. , 2006, Circulation journal : official journal of the Japanese Circulation Society.

[12]  Mónica Masotti,et al.  Seguimiento clínico y ecocardiográfico de pacientes con miocardiopatía hipertrófica obstructiva tratados con ablación septal percutánea , 2006 .

[13]  N. Lakkis,et al.  Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a systematic review of published studies. , 2006, Journal of interventional cardiology.

[14]  D. Holmes,et al.  Alcohol septal ablation for hypertrophic cardiomyopathy: Indications and technique , 2005, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[15]  P. Serruys,et al.  Percutaneous Versus Surgical Treatment for Patients With Hypertrophic Obstructive Cardiomyopathy and Enlarged Anterior Mitral Valve Leaflets , 2005, Circulation.

[16]  Tsung O. Cheng,et al.  Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: How much alcohol should be injected? , 2005, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[17]  W. Williams,et al.  Clinical and Echocardiographic Determinants of Long-Term Survival After Surgical Myectomy in Obstructive Hypertrophic Cardiomyopathy , 2005, Circulation.

[18]  W. Williams,et al.  Hypertrophic obstructive cardiomyopathy: comparison of outcomes after myectomy or alcohol ablation adjusted by propensity score. , 2005, The Journal of thoracic and cardiovascular surgery.

[19]  D. Fassbender,et al.  Echo-guided percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: 7 years of experience. , 2004, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

[20]  Barry J Maron,et al.  American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice G , 2003, Journal of the American College of Cardiology.

[21]  S. Nagueh,et al.  Complete heart block: determinants and clinical impact in patients with hypertrophic obstructive cardiomyopathy undergoing nonsurgical septal reduction therapy. , 2003, Journal of the American College of Cardiology.

[22]  Mario J. Garcia,et al.  Comparison of left ventricular diastolic function in obstructive hypertrophic cardiomyopathy in patients undergoing percutaneous septal alcohol ablation versus surgical myotomy/myectomy. , 2003, The American journal of cardiology.

[23]  M. S. Hamid,et al.  Septal myotomy-myectomy and transcoronary septal alcohol ablation in hypertrophic obstructive cardiomyopathy. A comparison of clinical, haemodynamic and exercise outcomes. , 2002, European heart journal.

[24]  N. Smedira,et al.  Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery. , 2002, Journal of the American College of Cardiology.

[25]  S. Ommen,et al.  Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. , 2001, Journal of the American College of Cardiology.

[26]  M. Verani,et al.  Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. , 1998, Circulation.

[27]  M. Verani,et al.  Role of myocardial contrast echocardiography during nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. , 1998, Journal of the American College of Cardiology.

[28]  W. Williams,et al.  Surgical Management of Hypertrophic Obstructive Cardiomyopathy , 1997 .

[29]  A. Pavie,et al.  [Long term results of the surgical treatment of obstructive hypertrophic cardiomyopathies]. , 1996, Archives des maladies du coeur et des vaisseaux.

[30]  U. Sigwart.  Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy , 1995, The Lancet.

[31]  David P Miller,et al.  Surgical management of hypertrophic obstructive cardiomyopathy. Early and late results , 1995 .

[32]  F. Delahaye,et al.  Postoperative and long-term prognosis of myotomy-myomectomy for obstructive hypertrophic cardiomyopathy: influence of associated mitral valve replacement. , 1993, European heart journal.

[33]  Z. Krajcer,et al.  Septal myotomy-myomectomy versus mitral valve replacement in hypertrophic cardiomyopathy. Ten-year follow-up in 185 patients. , 1989, Circulation.

[34]  Z. Krajcer,et al.  Mitral valve replacement and septal myomectomy in hypertrophic cardiomyopathy. Ten-year follow-up in 80 patients. , 1988, Circulation.

[35]  R. L. Fortune,et al.  Early and late results , 1983 .

[36]  K. Koyamada,et al.  [Surgical treatment of idiopathic hypertrophic subaortic stenosis]. , 1973, Kyobu geka. The Japanese journal of thoracic surgery.

[37]  Cleland Wp.  THE SURGICAL MANAGEMENT OF OBSTRUCTIVE CARDIOMYOPATHY. , 1963 .

[38]  E. Wigle,et al.  Results of ventriculomyotomy in muscular subaortic stenosis. , 1963, The American journal of cardiology.

[39]  E. Brockenbrough,et al.  Surgical treatment of idiopathic hypertrophic subaortic stenosis: technic and hemodynamic results of subaortic ventriculomyotomy. , 1961, Annals of surgery.

[40]  Z. Krajcer,et al.  Septal Myomectomy and Mitral Valve Replacement for Idiopathic Hypertrophic Subaortic Stenosis: Short- and Long-Term Follow-up , 2010 .

[41]  M. Sitges,et al.  [Clinical and echocardiographic follow-up of patients with hypertrophic obstructive cardiomyopathy treated by percutaneous septal ablation]. , 2006, Revista espanola de cardiologia.

[42]  D. Fassbender,et al.  [Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results in 66 patients with reference to myocardial contrast echocardiography]. , 1998, Zeitschrift fur Kardiologie.

[43]  W. Cleland.  THE SURGICAL MANAGEMENT OF OBSTRUCTIVE CARDIOMYOPATHY. , 1963, The Journal of cardiovascular surgery.